Jiangsu Aoyang Health Industryltd Past Earnings Performance
Past criteria checks 3/6
Jiangsu Aoyang Health Industryltd has been growing earnings at an average annual rate of 25.4%, while the Chemicals industry saw earnings growing at 7.8% annually. Revenues have been declining at an average rate of 17.8% per year. Jiangsu Aoyang Health Industryltd's return on equity is 41.2%, and it has net margins of 2%.
Key information
25.4%
Earnings growth rate
23.7%
EPS growth rate
| Chemicals Industry Growth | 12.1% |
| Revenue growth rate | -17.8% |
| Return on equity | 41.2% |
| Net Margin | 2.0% |
| Next Earnings Update | 29 Aug 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Jiangsu Aoyang Health Industryltd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 2,212 | 44 | 187 | 0 |
| 31 Dec 23 | 2,174 | 50 | 192 | 0 |
| 30 Sep 23 | 1,965 | -1 | 154 | 2 |
| 30 Jun 23 | 2,050 | -26 | 186 | 1 |
| 31 Mar 23 | 1,922 | -12 | 193 | 0 |
| 01 Jan 23 | 2,021 | -15 | 153 | 0 |
| 30 Sep 22 | 679 | 136 | 271 | 0 |
| 30 Jun 22 | 695 | 11 | 323 | 0 |
| 31 Mar 22 | 1,098 | -803 | 365 | 0 |
| 01 Jan 22 | 1,429 | -800 | 423 | 0 |
| 30 Sep 21 | 2,183 | -742 | 377 | -2 |
| 30 Jun 21 | 2,307 | -692 | 367 | -1 |
| 31 Mar 21 | 2,226 | 122 | 376 | 0 |
| 31 Dec 20 | 1,885 | -35 | 381 | 1 |
| 30 Sep 20 | 2,692 | -337 | 437 | 4 |
| 30 Jun 20 | 2,611 | -345 | 444 | 4 |
| 31 Mar 20 | 2,665 | -493 | 508 | 3 |
| 31 Dec 19 | 2,982 | -425 | 520 | 21 |
| 30 Sep 19 | 3,357 | -307 | 464 | 62 |
| 30 Jun 19 | 3,839 | -199 | 402 | 77 |
| 31 Mar 19 | 4,487 | -65 | 337 | 76 |
| 31 Dec 18 | 4,711 | 10 | 330 | 57 |
| 30 Sep 18 | 5,126 | 8 | 358 | 16 |
| 30 Jun 18 | 5,353 | 77 | 356 | 0 |
| 31 Mar 18 | 5,298 | 116 | 355 | 0 |
| 31 Dec 17 | 5,372 | 154 | 361 | 0 |
| 30 Sep 17 | 5,421 | 229 | 316 | 0 |
| 30 Jun 17 | 5,279 | 262 | 339 | 0 |
| 31 Mar 17 | 5,086 | 286 | 319 | 0 |
| 31 Dec 16 | 4,876 | 259 | 311 | 0 |
| 30 Sep 16 | 4,489 | 246 | 319 | 0 |
| 30 Jun 16 | 4,133 | 187 | 316 | 0 |
| 31 Mar 16 | 3,916 | 168 | 329 | 0 |
| 31 Dec 15 | 3,809 | 136 | 330 | 0 |
| 30 Sep 15 | 5,203 | 69 | 432 | 0 |
| 30 Jun 15 | 5,090 | 16 | 407 | 0 |
| 31 Mar 15 | 4,982 | -38 | 381 | 0 |
| 31 Dec 14 | 4,676 | -72 | 355 | 0 |
| 30 Sep 14 | 3,109 | -66 | 227 | 0 |
| 30 Jun 14 | 3,120 | -50 | 227 | 0 |
| 31 Mar 14 | 3,131 | -28 | 223 | 0 |
| 31 Dec 13 | 3,277 | 21 | 237 | 0 |
| 30 Sep 13 | 3,491 | 101 | 238 | 0 |
Quality Earnings: 002172 has high quality earnings.
Growing Profit Margin: 002172 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002172 has become profitable over the past 5 years, growing earnings by 25.4% per year.
Accelerating Growth: 002172 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 002172 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Chemicals industry (-14.8%).
Return on Equity
High ROE: Whilst 002172's Return on Equity (41.17%) is outstanding, this metric is skewed due to their high level of debt.